Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Al-Sawaf, Othman
113  Ergebnisse:
Personensuche X
?
1

High-risk stays high-risk: Bruton tyrosine kinase inhibitor..:

Al-Sawaf, Othman
Haematologica.  , 2024
Link: https://doi.org/10.3324/..
 
?
2

Chronic Lymphocytic Leukemia: Time-Limited Therapy in the F..:

Stumpf, Janina ; Al-Sawaf, Othman
Current Oncology Reports.  26 (2024)  2 - p. 136-146 , 2024
Link: https://doi.org/10.1007/..
 
?
3

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBIN..:

Yosifov, Deyan ; von Tresckow, Julia ; Giza, Adam...
HemaSphere.  7 (2023)  S3 - p. e14818fb , 2023
Link: https://doi.org/10.1097/..
 
?
4

Author Correction: Transcriptomic profiles and 5-year resul..:

Al-Sawaf, Othman ; Zhang, Can ; Jin, Hyun Yong...
Nature Communications.  14 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
5

P623: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTO..:

Al-Sawaf, Othman ; Jen, Min-Hua ; Hess, Lisa...
HemaSphere.  7 (2023)  S3 - p. e26114b3 , 2023
Link: https://doi.org/10.1097/..
 
?
6

Tislelizumab plus zanubrutinib for Richter transformation: ..:

Al-Sawaf, Othman ; Ligtvoet, Rudy ; Robrecht, Sandra...
Nature Medicine.  30 (2023)  1 - p. 240-248 , 2023
Link: https://doi.org/10.1038/..
 
?
7

Transcriptomic profiles and 5-year results from the randomi..:

Al-Sawaf, Othman ; Zhang, Can ; Jin, Hyun Yong...
Nature Communications.  14 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
8

Pirtobrutinib versus venetoclax in covalent Bruton tyrosine..:

Al-Sawaf, Othman ; Jen, Min-Hua ; Hess, Lisa M...
Haematologica.  , 2023
Link: https://doi.org/10.3324/..
 
?
9

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRO..:

Al-Sawaf, Othman ; Robrecht, Sandra ; Zhang, Can...
HemaSphere.  7 (2023)  S3 - p. e064430a , 2023
Link: https://doi.org/10.1097/..
 
?
10

Importance of Minimal Residual Disease in the Era of Target..:

Al-Sawaf, Othman
Acta Haematologica.  147 (2023)  1 - p. 22-32 , 2023
Link: https://doi.org/10.1159/..
 
?
11

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATI..:

Langerbeins, Petra ; Robrecht, Sandra ; Nieper, Pascal...
HemaSphere.  7 (2023)  S3 - p. e9488123 , 2023
Link: https://doi.org/10.1097/..
 
?
12

EXABS-208-CLL MRD+ at 1 Year of VenG: Stop Therapy:

Al-Sawaf, Othman
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S96-S97 , 2023
Link: https://doi.org/10.1016/..
 
?
13

Body composition and lung cancer-associated cachexia in TRA..:

Al-Sawaf, Othman ; Weiss, Jakob ; Skrzypski, Marcin...
Nature Medicine.  29 (2023)  4 - p. 846-858 , 2023
Link: https://doi.org/10.1038/..
 
?
14

CLL-246 Venetoclax-Obinutuzumab for Previously Untreated Ch..:

Al-Sawaf, Othman ; Zhang, Can ; Robrecht, Sandra...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S274-S275 , 2022
Link: https://doi.org/10.1016/..
 
?
15

Poster: CLL-246 Venetoclax-Obinutuzumab for Previously Untr..:

Al-Sawaf, Othman ; Zhang, Can ; Robrecht, Sandra...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S139 , 2022
Link: https://doi.org/10.1016/..
 
1-15